Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | CTSH | P09668 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292353 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL18328801 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL1783726 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL15756119 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL258985 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL231491 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8387889 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8972183 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8695376 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL9234715 | 0.93 | CTSK (0.52) | CTSKALDH1A1CTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20090220534-A1 | METHODS FOR IDENTIFYING T-CELL EPITOPES ASSOCIATED WITH IMPAIRED PEPTIDE PROCESSING AND APPLICATIONS OF THE IDENTIFIED EPITOPES | LEIDEN UNIVERSITY MEDICAL CENTER | 2009-09-03 | — | — | US | disclosed |
| WO-2009026579-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | PSMB1, PSME1, PSMB2 | CTSK 821/4885ALDH1A1 3881/4885CTSL 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.